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ABSTRACT 
The control protein Factor H is a crucial regulator of the innate immune complement system, where it 
is active on host cell membranes and in the fluid phase. Mutations impairing the binding capacity of 
Factor H lead to severe autoimmune diseases. Here, we studied the solution structure of full-length 
Factor H, in its free state and bound to the C3b complement protein. To do so, we used two powerful 
techniques, hydroxyl radical protein footprinting and chemical cross-linking coupled with mass 
spectrometry, to probe the structural rearrangements and to identify protein interfaces. The footprint 
of C3b on the Factor H surface matches existing crystal structures of C3b complexed with the N- and 
C-terminal fragments of Factor H. In addition, we revealed the position of the central portion of 
Factor H in the protein complex. Moreover, cross-linking studies confirmed the involvement of the C-
terminus in the dimerization of Factor H. 
 
INTRODUCTION 
Factor H (FH) is a key player in the regulation of the complement system, an essential component of 
human innate immunity. FH down-regulates the permanently active alternative pathway of the 
complement system to a basal level, thus preventing deleterious damage to host cells and tissues [1]. 
FH is an abundant circulating glycoprotein (0.1-0.5 mg/mL) that targets the membrane-bound C3b 
protein, a hub of the complement cascade. Active in the fluid phase, FH is the most important plasma 
inhibitor of the complement system. FH is endowed with an extraordinary diversity of modes of 
action, including competition with Factor B for binding to C3b, involvement as a cofactor in the 
cleavage of C3b by the protease I, and acceleration of the decay of the C3 convertase C3bBb. Many 
mutations in FH that impair these activities have been identified and are associated with severe 
diseases such as age-related macular degeneration, atypical hemolytic uremic syndrome and C3 
glomerulopathies [2]. The multiple pathways of action of FH rely on its broad binding capacity that 
can be seen as a multi-ligand platform for proteins such as C3b and the C-reactive protein, as well as 
for polyanionic carbohydrates such as heparin, sialic acid clusters and glycosaminoglycans (e.g. 
heparin sulfate) [3–8]. The structural features of FH promote this diversity of binding partners and 
mechanisms; numerous studies over the past decade have thus attempted to decipher the structure of 
FH [9]. However, given its molecular weight (MW 155 kDa) and its flexibility, FH resists 
conventional biostructural characterization methods, such as NMR and X-ray crystallography. The 
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flexibility of FH results from its unique structural organization comprising peptide linkers of 3 to 8 
amino acids that interconnect 20 homologous globular modules of about 60 residues in length and 
called short consensus repeats (SCR). This organization leads to a molecule that resembles a string of 
beads and that can adopt many different conformations. Most of the previous structural studies of FH 
at the molecular level have been carried out only on individual or a few concatenated SCR modules 
(Protein Data Bank (PDB): 2RLP, 2RLQ, 1HFH, 2UWN, 2KMS, 4B2R, 4B2S, 3SW0, 4K12) [10–
15]. The co-crystal structures of the N-terminal FH SCR modules [1-4] with C3b [16] (PDB: 2WII), 
and the C-terminal FH SCR modules (19-20) with C3d [17–19] (PDB: 3OXU) have provided 
important clues on the decay of C3 convertase and the co-factor I activities of FH, as well as its role in 
the self/non-self discrimination. These two major functional terminal regions of FH have been 
recently engineered to form a minimal size, functional FH construct [20]. However, the only studies 
on the full-length molecule employed electron microscopy, X-ray and neutron scattering, and 
analytical ultracentrifugation, providing low to medium resolution data [21–23]. These studies have 
revealed multiple fold-back structures in FH and its capacity to self-associate, consistent with its 
flexible structure [24,25]. 
Herein, we probed the structure of the full-length, intact FH molecule in solution by chemical cross-
linking and X-ray synchrotron-mediated hydroxyl radical footprinting (HRPF) combined with high-
resolution mass spectrometry (MS). HRPF combined with MS has recently emerged as a powerful 
technique that provides single amino-acid resolution on large proteins and macromolecular assemblies 
that are otherwise inaccessible via conventional approaches [26–28]. The hydroxyl radical (∙OH) is an 
efficient labeling reagent that can be generated by the radiolysis of water molecules upon irradiation 
of the protein sample by a synchrotron X-ray beam. ∙OH reacts on a fast timescale with a wide range 
of amino acids, leading to their oxidation and to a mass increase of +16 Da (or a higher multiple) 
corresponding to the incorporation of oxygen [29]. 
In this study, the full size FH was irradiated in solution and the oxidized amino acids were identified. 
The quantitative determination of the oxidation level using LC-MS/MS analysis led to the definition 
of the solvent-accessible surfaces on the 20 SCR modules of FH. Furthermore, given that the 
footprinted regions can vary with conformational rearrangement, ligand binding or biomolecular 
interactions, we therefore also investigated the solvent-accessible surfaces of the FH molecule in a 
complex with C3b. We assessed how the different SCR modules are involved in the interaction with 
C3b, in an attempt to shed light on the FH structural organization in the FH-C3b complex.  
 
EXPERIMENTAL PROCEDURES 
 
Materials and Reagents 
All materials were of analytical grade. DL-dithiothreitol (DTT), iodoacetamide, ammonium 
bicarbonate, phosphate-buffered saline (PBS; 10 mM phosphate buffer, 2.7 mM potassium chloride 
and 137 mM sodium chloride, pH 7.4) and urea were all purchased from Sigma-Aldrich. Cross-
linking reagents BS3-d0 and BS3-d4 were purchased from Thermo Scientific. Acetonitrile was 
obtained from Fluka, formic acid from Normapur and sequencing-grade modified porcine trypsin 
from Promega. Complement system proteins C3b and FH purified from human plasma were obtained 
from Calbiochem (MerckMillipore, Darmstadt, Germany). All buffers and solutions were prepared 
using ultra-pure 18 MΩ water (MilliQ). 
 
Synchrotron X-ray footprinting of Factor H 
Synchrotron irradiation of FH was performed using the Metrology beamline at the SOLEIL 
synchrotron facility (Saint Aubin, France). The experiment was conducted on the hard X-ray branch 
of the beamline that emits monochromatic photons in the 100 eV to 40 keV energy range, and also 
allows access to the synchrotron white radiation. This latter configuration was used for the X-ray 
footprinting experiments. 
First, 2 µM FH was prepared in PBS. The QFM-400 Micro-Volume Quench Flow (Bio-Logic SAS) 
stopped-flow system was used to deliver the samples in front of the beam and regulate the irradiation 
time. Then, 14 μL of the 2 μM FH solution was loaded into the instrument and mixed with 0.01 M 
PBS or C3b solution at a 1:1 molar ratio for 1 s in the mixing chamber. The reaction mixture was 
delivered to the quartz capillary placed in front of the beam and FH samples in the absence or 
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presence of C3b were exposed to various radiation times ranging from 0 to 150 ms. Computer-
controlled Quench Flow Apparatus enabled immediate quenching of the remaining free hydroxyl 
radicals with 20 μL of 100 mM methionine, within 10 ms from X-ray exposure. All experiments were 
carried out at 21°C and the irradiated samples were stored at -80°C. 
 
Chemical cross-linking of Factor H 
Cross-linking of FH was performed with the homobifunctional sulfo-NHS ester cross-linker reagent 
bis(sulfosuccinilidyl) suberate (BS3-d0 and -d4), characterized by a 11.4 Å spacer arm (Thermo 
Scientific). BS3 (70 mM in water) was added to FH in a 10:1 molar ratio. After 1 h of incubation on 
ice, the reaction was stopped with the addition of cold ammonium bicarbonate (50 mM, final 
concentration). Samples were then immediately mixed with denaturing Laemmli buffer and heated to 
95°C for 5 min for subsequent SDS-PAGE analysis. SDS-PAGE was carried out on 6% Tris-glycine 
polyacrylamide gels following the standard method described by Laemmli [30]. After migration, the 
gel was stained with Instant BlueTM (Expedeon). 
 
In-solution and in-gel proteolytic digestions 
Irradiated FH samples in PBS were vacuum-dried and diluted in 14 µL ultra-pure water. Prior to 
reduction, 3 µL of 8 M urea in 400 mM ammonium bicarbonate was added to the sample. Samples 
were then reduced with the addition of DTT (4.2 mM, final concentration) for 45 min at 37°C, and 
then alkylated with iodoacetamide (7.6 mM, final concentration) for 30 min in the dark. To dilute the 
urea, 14 µL of ultra-pure water was added before adding trypsin (1:25, w/w). Trypsin digestion was 
carried out overnight at 37°C and was terminated by freezing the samples. Prior to nano LC-MS/MS 
analysis, protein digests were vacuum-dried and re-suspended in 14 µL of 98% H2O, 2% CH3CN, 
0.1% HCOOH (solvent A). 
Cross-linked samples separated by SDS-PAGE underwent in-gel digestion. The protein bands were 
excised and destained with 30% ethanol, reduced with the addition of 50 µL of 10mM DTT and 
alkylated with 50 µL of 55 mM iodoacetamide. In-gel digestion was carried out overnight at 37°C by 
adding 20 µL of trypsin at a concentration of 12.5 ng/µL. The resulting peptides were extracted by 
subsequent incubation of the gel pieces in the following extraction solutions: 60% CH3CN, 0.1% 
HCOOH; 80% CH3CN, 0.1% HCOOH; and 100% CH3CN, 0.1% HCOOH. Supernatants were 
recovered and vacuum-dried. Pellets were re-suspended in 10 µL of solvent A prior to nano LC-
MS/MS analysis. 
 
Nano liquid chromatography tandem mass spectrometry of irradiated samples 
Nano LC-MS/MS analyses were performed on a Dual Gradient Ultimate 3000 chromatographic 
system (Dionex) coupled to a LTQ-Orbitrap™ XL mass spectrometer (Thermo-Fisher Scientific) 
equipped with a nanospray source operating in positive ionization mode.  
First, 2 µL of sample was loaded onto a C18 pre-column (Acclaim PepMap C18, 5 mm length x 300 
µm I.D., 5 µm particle size, 100Å porosity, Dionex) and desalted for 5 min with solvent A. After this 
step, peptide separation was carried out on a C18 capillary column (Acclaim PepMap C18, 15 cm 
length x 75 µm I.D., 3 µm particle size, 100 Å porosity, Dionex) with a gradient starting at 100% 
solvent A, ramping to 70% solvent B (80% CH3CN, 20% H2O, 0.1% HCOOH) in 30 min, then to 
100% solvent B over 5 min (held for 2 min) and finally decreased to 100% solvent A in 10 min. 
A parent list was created using MS-Digest (Protein Prospector, UCSF) with the following parameters: 
trypsin digestion, 1 missed cleavage, peptide mass: 400-1600. Constant modifications: carbamido-
methyl; variable modifications: oxidation Met, report multiple charges. The obtained parent list was 
then manually modified by adding +15.9949 Da to the peptide mass generated by MS-Digest. A 
parent list including double oxidation (+31.9898 Da) was also created, but only a few multiply 
oxidized sites were identified (data not shown), probably due to the applied footprinting conditions. 
For this reason, only single oxidation (+15.9949 Da) modifications were monitored in this study. 
One series of MS analyses (ITMS2 analyses) consisted of acquisition cycles composed of one MS 
scan in the Orbitrap analyzer (profile mode; resolution, 60000; m/z range, 400-2000) followed by five 
MS/MS scans (CID fragmentation and detection in the linear ion trap analyzer; centroid mode; 
isolation width 3 Da) triggered on the five most intense species from the parent list detected in the 
preceding MS scan, at a normalized collision energy of 35%. To exclude multiple MS/MS analyses 
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for the same peptide, dynamic exclusion of 45 s was applied with a repeat count of 1, repeat duration 
of 30 s and an exclusion mass width of +/- 7ppm. Singly charged ion species were excluded from 
fragmentation. 
 
Footprinting data analysis  
MS data were processed using ProtMapMS software [31] (Neoproteomics, USA), and were also 
manually validated in raw spectra using Xcalibur version 2.1.0. (Thermo Scientific). The specific sites 
of modification for each peptide were assigned using a Mascot server and manually validated. 
The proportion of unmodified peptides defined as the ratio of unmodified peptides to the total amount 
of peptides (modified and unmodified) was calculated for each exposure time. 
The rate of oxidation of a given peptide was determined from the dose-response plots of the 
proportion of unmodified peptides as a function of X-ray exposure time (ms). The dose-response plots 
were fitted to the following equation: y=e-kt, where k is the first-order rate constant and t is the 
exposure time. Then, the dose-response curves generated for each FH peptide were used to compare 
the degree of oxidation of FH in both states (unbound and bound to C3b) and calculate the degree of 
protection. 
Solvent-accessible surface areas (SASA) of modified FH residues were calculated using GETAREA 
software [32], based on the available in-solution and crystal structural data of modules and full-length 
FH (details given in Table 1). 
 
Nano liquid chromatography tandem mass spectrometry of cross-linked samples 
Nano LC-MS/MS analyses of the cross-linked samples were performed in the same chromatographic 
conditions as those used for the irradiated samples, except only  
5 µL of sample was injected.  
One series of MS analyses (ITMS2 analyses) consisted in acquiring cycles composed of one MS scan 
in the Orbitrap analyzer (profile mode; resolution, 60000; m/z range, 400-2000) followed by 10 
MS/MS scans (CID fragmentation and detection in the linear ion trap analyzer; centroid mode; 
isolation width, 3 Da) triggered on the 10 most intense species detected in the preceding MS scan, at a 
normalized collision energy of 35%. To exclude multiple MS/MS analyses for the same peptide, 
dynamic exclusion of 20 s was applied with a repeat count of 1, repeat duration of 30 s and an 
exclusion mass width of +/- 7ppm. Singly and doubly charged ion species were excluded from 
fragmentation. 
 
Cross-linking data analysis 
Bioinformatics analysis of cross-linking spectra was conducted as reported by Redeker et al. [33]. 
RAW data acquired on LTQ-Orbitrap mass spectrometer were converted to .MZXML files using the 
MSConvert software [34]. The resulting .MZXML files were processed with the DeconTools 
AutoProcesor (http://omics.pnl.gov/software/decontools-decon2ls) to de-isotope mass spectra. The 
resulting .csv files were analyzed using Viper software [35], to identify the d0/d4 peptide pairs 
corresponding to a mass difference of 4.0247 Da as a signature of peptides that reacted with at least 
one molecule of BS3-d0/d4. A list of peptide pairs with a maximum mass tolerance of 10 ppm was 
generated. Mass deviation and peptide elution time were used to manually filter the list of peptide 
pairs, corresponding to candidate cross-linked peptides or mono-linked or loop-linked peptides. The 
list of light and heavy precursor masses was used to identify the peptides of BS3-d0/d4 using the 
xQuest software [36]. MS/MS spectra of the tracked cross-linked peptides were further analyzed 
manually to confirm their identification. 
 
RESULTS 
 
Hydroxyl radical protein footprinting of the full-size Factor H molecule 
The SASA of the full-size FH molecule, either alone or in presence of the C3b protein, was probed 
using HRPF with the white X-ray beam of the Metrology beamline at the SOLEIL synchrotron 
facility (France). Irradiated samples underwent tryptic proteolysis and the resulting oxidized FH 
peptides were identified and quantified by nano LC-nano electrospray ionization (ESI) MS/MS. 
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The sequence coverage of irradiated FH using MS/MS was on average 73% throughout the entire 
molecule, providing for a robust analysis of vast portions of the FH molecule (Figure 1). Similar 
sequence coverage was obtained for non-irradiated FH (data not shown), indicating that X-ray 
exposure did not damage the FH structure, in agreement with a previous study showing that HRFP 
does not affect protein structure [37]. The integrity of FH after irradiation was also confirmed by 
MALDI-TOF analysis (data not shown). Identification of the oxidation sites was based on the 
detection of peptides with a change in mass due to the hydroxyl radical reaction with an amino acid 
side chain. Because the MS/MS method targets only the peptides with a mass shift of + 15.9949 Da 
resulting from the incorporation of oxygen, no other modifications caused by hydroxyl radicals were 
detected.  
The 23 oxidized residues of FH were identified in a reproducible manner (Table 1), based on both 
automatic and manual investigations of MS/MS spectra. In order of frequency, the affected amino 
acids were Leu, Ile> Met, Tyr, His> Phe, Val, in agreement with the reactivity towards hydroxyl 
radicals reported in the literature [38]. They were distributed throughout almost all of the SCR 
modules, except SCR modules 4, 6, 15 and 19, with the main occurrences in SCR modules (1-2) (each 
with three oxidized residues) and (7-8 and 14) (each with two oxidized residues). Representative 
MS/MS spectra of two oxidized FH peptides (92-109) and (110-127) belonging to the SCR2 module 
are shown in Figure 2. 
The obtained experimental footprinting data were compared with the SASA values of the FH amino 
acid side chains obtained from existing structural data. Note that no crystallographic structure of full-
length FH is available to date, and that only the structural data of individual recombinant FH modules 
obtained either by NMR or crystallographic studies [11,13–15,39,40] could be used for comparison. 
For most of the oxidized sites identified on the full-length FH molecule in this study, the level of 
oxidative labelling was in agreement with the solvent accessibility previously reported for isolated FH 
modules (see below). We therefore produced a map of oxidized residues on the full-length FH 
molecule by combining the structural data from the different FH modules (Figure 3). 
The following eight oxidation sites were identified in SCR modules (1-5) based on MS/MS analysis: 
Tyr24 (SCR1), Met46 (SCR1), Val54 (SCR1), Leu80 (SCR2), Leu103 (SCR2), Ile120 (SCR2), 
His173 (SCR3) and Leu262 (SCR5). SASA values of the seven oxidized residues within modules 1-3 
were calculated from the NMR structures of SCR(1-2) (PDB : 2RLP) and SCR(2-3) (PDB ID: 
2RLQ). These residues, which reacted with the hydroxyl radicals, were moderately to highly exposed 
to the solvent in SCR modules (1-2) and (2-3) [39] (SASA ≈ 10 to 30 Å2). No solution or 
crystallographic structures are currently available to assess the solvent accessibility of SCR5; 
therefore no SASA value could be determined for Leu262 (SCR5). However, its modification by 
hydroxyl radicals indicates that Leu262 is likely exposed (i.e. SASA ≥ 10 Å2) to the solvent in free 
FH. 
Four oxidized residues were detected in SCR modules (7-8): His399 (SCR7), Met414 (SCR7), Tyr449 
(SCR8) and Ile474 (SCR8). According to the crystal structure of mutated SCR(6-8) in complex with 
sucrose-octasulfate (SOS) [13] (PDB: 2UWN), His399 and Met414 are highly exposed to the solvent 
(SASA, 65.42 and 85.70 Å2, respectively). This surface exposition is consistent with oxidation of 
His399 and Met414 by hydroxyl radicals in unbound FH. Oxidation of these residues is very 
interesting in regard to their proximity to binding sites for polyanions [7] and C3b [41] in SCR7 and 
confirms the high reactivity of this region of FH. 
Residues Tyr449 and Ile474 in SCR8 were modified by hydroxyl radicals, suggesting that these 
residues are likely exposed to the solvent in free FH. However, these two residues are buried (SASA= 
0.31 and 7.37 Å2, respectively) in the crystallographic structure of SCR(6-8) complexed with SOS 
[13] (shown in Figure 4).  
Six oxidized residues were detected in SCR modules (10-14), including two oxidized residues in 
SCR14, indicating solvent accessibility of this central part region of FH for which no crystallographic 
structure is available to date. Nevertheless, solution structures of modules (10-15) and (10-12) have 
been recently investigated by analytical ultra-centrifugation, small-angle X-ray scattering (SAXS) and 
NMR [14,15], indicating a relatively rigid and compact structure. These studies led to the deposition 
of high-resolution structures of FH SCR modules (10-11), (11-12) and (12-13) in the (PDB: 4B2R, 
4B2S and 2KMS, respectively), but the structure of SCR14 remains unknown, due to the difficulties 
in obtaining recombinant pairs of SCR(13-14) and SCR(14-15) [15]. All oxidized residues in 
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SCR(10-13) exhibited significant solvent accessibilities (SASA ≥30 Å2), in agreement with the NMR 
solution structure data of SCR(10-11), (11-12) and (12-13). 
Finally, no oxidation was found in SCR19 containing the C3b binding site. Less than half residues (28 
out of 58) were solvent accessible. These potential oxidation sites may be shielded by a structural 
arrangement of SCR19 between SCR18 and SCR20. 
 
Hydroxyl radical footprinting of Factor H in presence of C3b 
FH was also exposed to synchrotron X-rays in presence of its binding partner C3b in a 1:1 molar ratio, 
and oxidation sites were compared between the two states of FH (alone and with C3b). Sequence 
coverage of FH irradiated with C3b was identical to that of FH alone (74%), providing for a 
meaningful comparison of the extent of oxidation between the two states of FH. 
MS/MS analysis of the C3b-FH mixture revealed significantly decreased oxidation of FH, with only 
nine residues showing a typical mass shift of +15.9949 Da. Among them, eight oxidized residues 
were also detected in FH alone (Val54 in SCR1, Met414 in SCR7, Met497 in SCR9, His746 in 
SCR13, Phe945 in SCR16, Ile981 in SCR17, Ile1041 in SCR18 and Tyr1159 in SCR20), and only 
one residue (Met927 in SCR16) was differentially exposed to the solvent in FH with C3b. This 
significant decrease in hydroxyl radical footprinting likely indicates a shielding effect due to C3b, 
with multiple interaction sites between the two proteins, and a possible conformational change of FH 
upon C3b binding. 
Table 2 summarizes the oxidized residues detected in FH in the presence of C3b. SASA values were 
compared between the two states of FH for only two oxidized residues Val54 (SCR1) and Tyr1159 
(SCR20) because they belong to previously reported X-ray crystallographic structures of FH[1-4] in 
complex with C3b [16], and FH[19-20] with C3d [17] (PDB: 2WII and 3OXU, respectively). We 
noticed a significant decrease in solvent exposure for these two residues, especially for Tyr1159 in 
SCR20 (from 94.6 Å2 to 77.5 Å2). 
Differences in oxidized sites between FH irradiated with or without C3b are shown in Figure 3. One 
of the most important variations was observed in the N-terminal domain which comprised eight 
oxidized residues in SCR(1-3, 5) in FH irradiated alone and only one in presence of C3b. A 
significant decrease in modified residues was observed in SCR1 (one oxidized residue in the C3b-FH 
complex instead of three in unbound FH) as well as in SCR2, SCR3 and SCR5 that lacked any 
modified residues. A major change in oxidation was also found in the central part of FH, which 
showed only one oxidized residue in SCR7 (compared with two in unbound FH), and the lack of 
oxidation in SCR8, SCR10, SCR11, SCR12 and SCR14. 
The oxidation rates of modified FH peptides were determined from dose-response plots and compared 
to those obtained in the presence of C3b (Figure 5). Oxidation rate constants decreased for all FH 
peptides from the FH-C3b incubation, indicating a lower accessibility of these residues in presence of 
C3b. This lower reactivity is in line with the lower footprinting of FH in presence of C3b as 
mentioned above. Together, these results suggest that C3b shields these residues and that FH 
potentially undergoes a conformational change.  
For a given modified peptide, the variation in its oxidation rate between two states of the protein can 
be expressed as a degree of protection determined by the ratio of the slope values of the dose-response 
curves. According to previous studies [42], a difference in oxidation rates less than 20% (i.e. ratio ≈ 
0.8-1.2) is considered as insignificant, suggesting little or no change in solvent accessibility. On the 
other hand, a decrease in the oxidation rate greater than 20% (i.e. ratio ≥ 1.2) indicates a significant 
decrease in the solvent accessibility of the peptide, which may result from protection through 
biomolecular protein-protein interactions. On the contrary, a ratio below 0.8 indicates an increase in 
the solvent accessibility of the investigated zone. 
We observed a ratio of ≥4.0 for the 15 peptides located in SCR1, SCR3, SCR5, SCR7, SCR8, SCR10, 
SCR11, SCR12 and SCR14 that were non-oxidized in presence of C3b, thus confirming a high degree 
of protection upon C3b binding (Figure 6). These peptides are strong candidates for participation in 
the interface of the C3b-FH complex. 
Ratios ranging between 1.2 and 4.0 fold were observed for the eight peptides that were detected in 
oxidized form in the presence of C3b, indicating moderate protection of these peptides distributed 
throughout the FH structure. Only one peptide (915-940, located in SCR16) showed increased solvent 
accessibility and hence increased solvent exposure upon complex formation. 
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A decrease in the oxidation of residues located in SCR(7-8) of FH upon C3b binding suggests their 
implication in a C3b-FH interaction zone. This is consistent with the weak C3b-binding site in 
SCR(6-8) proposed by Schmidt et al. [41]. 
An dramatic decrease in oxidation was also observed in SCR(10-14): only one residue (His746) was 
detected as oxidized compared with six modified residues in free FH. 
Finally, Tyr1159 located in SCR20 is the only oxidized residue detected in the C-terminal part of FH. 
 
Chemical cross-linking of Factor H 
The solvent accessibility study of FH residues provides data on the exposure of the different modules 
depending on their location in the FH molecule. To obtain further insight into the structural folding 
and dimerization of FH, the full-length FH molecule was subjected to chemical cross-linking 
experiments coupled with MS. To do so, FH was incubated in a ratio of 1:10 with the 
homobifunctional cross-linker NHS-ester BS3 (11.4 Å spacer arm), which targets mainly the solvent 
accessible lysine residues, and to a lesser extent, serine, threonine and tyrosine side chains [43]. FH 
and potential cross-linked species were separated by SDS-PAGE. In addition to FH migrating at the 
expected molecular weight (i.e. 150 kDa), an additional species was observed with an apparent 
molecular weight of ≈300 kDa, corresponding to a dimer of FH. The dimer species and monomeric 
FH were in-gel digested and the resulting peptides were separated and analyzed using nano LC-
MS/MS. 
The search for cross-linked peptides was carried out by combining different software, as described by 
Redeker et al. [44]. We found 13 cross-linked peptides belonging to FH. They were mainly detected 
in the dimer species (10 interpeptides and 2 intrapeptides), whereas only 3 cross-linked species were 
identified in the FH monomer. Among all these cross-linked peptides, two were identified in both 
bands. Table 3 groups the cross-linked peptides of FH according to the following nomenclature 
proposed by Schillig et al. [45]: dead-end (type 0), intrapeptide (type 1) and interpeptide (type 2). In 
accordance with the reactivity of residues towards BS3 NHS-ester [43], the majority of cross-linked 
amino acids were lysine residues (52% of the cross-linked residues), while serine and threonine 
accounted for 36% and 12% of cross-linked residues, respectively. No reaction with tyrosine side 
chains was detected. It is worth noting that a large part of bridged residues belong with regions such 
as in SCR3, SCR8, SCR11, SCR13, SCR16 and SCR20, where hydroxyl radical-oxidized were 
detected upon HRPF experiment, thus confirming solvent accessibility and reactivity of these regions 
of FH. 
Secondly, cross-linking experiment allowed us to investigate the dimerization state of FH. We 
assumed that the interpeptides identified by MS/MS in the FH dimer and not in FH monomer 
originate from two bridged FH molecules. Figure 8A shows a mass spectrum of interpeptide located 
in SCR20, demonstrating that two FH molecules were proximal during cross-linking reaction. 
However, the detection of the interpeptide SSQESYAHGYK-WTAK (868-878/1165-1168) from 
SCR15 and SCR20 not only in the dimer species, but also in FH monomer indicates that this 
interpeptide may also arise from neighboring peptides within one FH molecule. This result suggests 
that the SCR15 and SCR20 modules are close enough to each other within one FH molecule, although 
a previously reported SAXS-derived structural model of FH [25] (PDB: 3GAV-1) showed distant 
SCR15 and SCR20 modules, a 164 Å distance separating Ser872 and Thr1166 (i.e. 14 times longer 
than the BS3 spacer arm). Given the flexibility of FH, we assume that it can adopt several 
conformations in solution, among them conformations where SCR15 and SCR20 are much closer than 
in the SAXS model 3GAV-1 model, and thus allowing cross-linking reactions to occur within the 
same molecule. In addition, the moderate ionic strength used in this study (114 mM NaCl vs. 137 mM 
for the 3GAV-1 model) may have favored a more folded-back conformation of FH. Furthermore, the 
high net charge difference between SCR20 (+8) and SCR15 (-4) may also contribute to interactions 
between these two modules [25]. This result underlines the high flexibility of FH, and, in this respect, 
it is noteworthy that a major part of the detected cross-linked peptides involved the C-terminal module 
SCR20, in agreement with a recent study[46] which also reported multiple cross-linking sites in 
SCR20 of monomeric FH. 
Cross-linked peptides within the SCR20 module involved residues Lys1168 and Lys1170. These 
residues are close enough (8.1 Å) to give rise to an intrapeptide cross-link (WTAKQKLYSR). They 
were also involved in the WTAKQK- WTAKQK (1165-1170/1165-1170), QKLYSR-QKLYSR 
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(1169-1174/1169-1174) and QKLYSR- WTAKQK (1169-1174/1165-1170) interpeptides detected in 
the FH dimer. These C-terminal interpeptides, involving two FH molecules, are consistent with a 
previous report showing the capacity of FH to self-associate, with a dimerization site in its C-terminus 
[47].  
 
DISCUSSION 
 
We mapped the FH surface using HRPF and chemical cross-linking coupled with MS. HRPF can 
provide high-resolution data on whole protein molecules in solution. In this study, we carried out the 
high-resolution HRPF analysis on the full-length FH molecule (150 kDa) alone and FH in interaction 
with C3b (330 kDa). HRFP has been used to study protein complexes such as gelsolin (80 kDa) [48], 
but, to our knowledge, there have been only a few studies on complexes of over 200 kDa [49,50]. We 
compared the oxidation sites, when possible, with solvent accessibility data available from 
crystallographic and solution-NMR structures of FH modules in the PDB. The identification of 
oxidized side chains provided clues on the solvent accessibility of FH peptides, which is particularly 
interesting in regard to several SCR modules whose structure is not yet known (e.g. SCR5 and 
SCR14). Moreover, assuming modification of the solvent-accessibility surface of FH upon interaction 
with C3b, the accurate measurement of the oxidation pattern was used to construct a map of 
interaction sites on FH. 
Twenty-three residues located in 17 SCR modules were oxidized by hydroxyl radicals, showing the 
presence of reactive sites on the FH surface. FH contains more than 400 hydroxyl radical sensitive 
residues (Met, Cys, Trp, Tyr, Phe, His, Pro and Leu), yet many of them are protected within the 
folded structure of the protein and therefore they are not accessible for hydroxyl radical, or are located 
in the non-covered sequence of FH. Having been selected on their high signal-to-noise ratio and 
reproducibility, these oxidized residues represent a robust mapping of the solvent accessible area of 
FH. Roughly 30% of oxidized amino acids detected in unbound FH were located in the SCR(1-4) 
modules, highlighting this N-terminal domain as a solvent-accessible area of FH. This result confirms 
the high reactivity of this region of FH already known to contain one C3b binding site [16]. Four 
oxidized amino acids were identified in the SCR7 and SCR8 modules, which encompass the heparin 
and C3b binding sites [41], as well as binding site for pathogen components like Streptococcus 
pneumoniae protein PspC [46]. Interestingly, several residues within the SCR(10-16) modules were 
also oxidized, indicating that this central portion of FH is exposed to the solvent and may contain 
interaction sites.  
Fifteen residues mapped on the surface of free FH were no longer available for hydroxyl radical 
attack when FH was in a complex with C3b, providing valuable information on interaction zones with 
C3b as well as on the intra-molecular re-arrangement of FH upon C3b binding. 
The decrease in both the number of oxidized residues and the reactivity towards hydroxyl radical 
observed in SCR[1-3] is consistent with the crystallographic structure of C3b-FH(1-4) [16], in which 
the interface between C3b and the four N-terminal modules of FH stretches over 100 Å. The oxidized 
residues identified along the first three N-terminal SCR modules of FH are located in close proximity 
to the C3b surface identified in the crystallographic structure of C3b-FH(1-4). This can explain the 
decreased or inhibited oxidation of residues located in this region, as observed with His173 in SCR3. 
This residue is located within a very short distance to the macroglobulin-2 domain of C3b in the 
crystallographic structure of C3b-FH(1-4) [16] (about 4 and 3.3 Å away from the C3b residues Ser159 
and Gln161, respectively) decreasing the SASA from 69.27 to 18.15 Å2 upon C3b binding[16].  
Tyr24 showed decreased reactivity towards hydroxyl radicals that could not be attributed to direct 
protection by C3b binding, as determined from the crystal structure of the C3b-FH(1-4) complex. The 
decrease in Tyr24 reactivity is likely explained by a conformational adjustment of FH upon C3b 
binding, as illustrated by the significant decrease in the SASA of Tyr24 from 37 Å2 in unbound FH to 
5.57 Å2 in FH complexed with C3b. Leu103 and Ile120 in SCR2 were highly oxidized in free FH, in 
agreement with their high SASA values calculated from the NMR-derived structure of SCR(1-2) ( 
PDB: 2RLP)  [10]. Interestingly, these residues were only detected in the unoxidized form in the 
presence of C3b, whereas their SASA values remained high in the C3b-FH(1-4) complex (from 99.83 
to 90.37 Å2 for Leu103 and from 63.66 to 54.47 Å2 for Ile120) as observed on the corresponding 
crystallographic structure (PDB: 2WII) [16]. Leu103 and Ile120 were not directly involved in the 
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interaction with C3b although in close proximity to the C3b surface in the C3b-FH(1-4) structure 
(Figure 7). The observed lack of oxidation indicates decreased accessibility of Leu103 and Ile120 in 
the full-length FH in the presence of C3b in solution. This change in accessibility suggests a different 
structural arrangement between the in-solution conformation and the crystal structure, which may 
arise from different constraints applied on these residues in the full-length FH molecule compared 
with a partial, four-module FH molecule.  
Residues His399, Tyr449 and Ile474 located in SCR(7-8) were modified by hydroxyl radicals only in 
free FH, but remained unmodified in the complex. Interestingly, this loss of accessibility is consistent 
with a previously reported weak binding site for C3b situated in this region of FH [3,41], but diverges 
from the proposed models for the C3b-FH complex [13,17], in which FH acquires a bent-back 
structure and binds with C3b through only the SCR (1-4) and (19-20) modules. Surface plasmon 
resonance (SPR) studies [41] have demonstrated that SCR(6-8) and possibly SCR9 have low affinity 
for C3b. Our data confirm these findings, because residues His399, Tyr449 and Ile474 of SCR(7-8) 
became inaccessible to hydroxyl radicals in the presence of C3b, whereas Met497 located in SCR9 
was oxidized in free and bound FH, indicating that this module does not participate in the C3b-FH 
complex interface. 
In the crystallographic structure of SCR(6-8) in complex with SOS (PDB: 2UWN) [13], His399 is 
exposed to the solvent (SASA = 65.42 Å2) and does not interact directly with this heparin-mimicking 
sugar. However, the absence of oxidation of His399 in the presence of C3b suggests either that the 
C3b molecule shields this residue, or that there is a different conformational arrangement of the SCR7 
module in the full-length FH molecule compared with a partial FH molecule composed of isolated 
modules SCR(6-8). The former hypothesis assumes a third C3b-binding site on FH[41]. For example, 
Met414, which is located on the opposite face of SCR7, was oxidized in the unbound and bound states 
of FH, suggesting that only one side of SCR7 may interact with C3b, whereas the other face remains 
exposed to the solvent. This SCR(6-8) region may therefore be involved in the binding of both C3b 
and glycosaminoglycans. 
Neighboring Tyr449 and Ile474, both located in SCR8, were modified by hydroxyl radicals in free 
FH, indicating a solvent-exposed patch, but they are buried in the crystallographic structure of SOS-
SCR(6-8). This discrepancy may again underline a difference in conformation of these modules in the 
full-size FH in solution and in isolated modules in an X-ray crystal. In addition, artificial constraints 
on the SCR(6-8) co-crystal due to crystal packing and binding of the highly sulfated carbohydrate 
ligand SOS cannot be ruled out. 
The central SCR(10-14) module exhibited six oxidized residues in free FH, however only His746 
(SCR13) remained modified in the presence of C3b, although to a lesser extent. This central region is 
not known to host a C3b binding site. Nevertheless, the observed oxidation pattern leads to the 
hypothesis that this central region may be close to C3b in the FH-C3b complex, and may thus be 
protected from hydroxyl radicals by a neighboring C3b molecule. 
Modification of Leu826 and Leu843 (SCR14) by hydroxyl radicals in the unbound FH gave the first 
insight into the solvent accessibility of these residues, indicating that they are solvent-accessible, 
because modification of a residue’s side chain is unlikely when its SASA is below 10 Å2.  
In the C-terminal modules SCR(19-20), which contain C3b and glycosaminoglycan binding sites 
[17,41], only one residue (Tyr1159, SCR20) was identified as oxidized in both forms of FH. Although 
Tyr1159 is not located directly in the C3b-FH(19-20) interface zone, it is close to Tyr1190 in SCR20 
(about 20 Å away), which interacts with Asp1093 of C3b. Given that this residue becomes moderately 
protected in the C3b-FH complex, the neighboring C3b may shield Tyr1159 [17]. The low oxidation 
level of the C-terminal modules SCR(19-20) may be also a result of the “J-shape” of this C-terminal 
region [40] showing a 122° angle between SCR18 and SCR19 that can impede the accessibility of 
SCR19 to hydroxyl radicals. What is more, a difference in conformation, and thus in solvent 
accessibility, between modules SCR(19-20) within full-length of FH and isolated modules FH(19-20) 
in complex with C3b cannot be ruled out. Interestingly, the full-length FH bind weakly to C3d (i.e. the 
TED domain of C3b)[41] while the isolated modules SCR(19-20) bind to C3d with a good 
affinity[17,20], which suggests that the C-terminal region of full-length FH may adopt a conformation 
masking reactive and binding sites buried in modules SCR(19-20). A recent study confirmed this 
protected conformation of the C-terminal domain of full-length FH, which becomes exposed upon 
binding of the N-terminal domain of bacterial protein PspC[46]. The low oxidation level observed 
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here provides an additional evidence of a locked conformation of the C-terminal modules SCR(19-20) 
within full-length FH. 
The self-association of FH was first reported by Nan et al. [47], although it is still under debate as to 
its occurrence and mechanism in natura. Dimerization may mask some binding sites, which can affect 
the regulation of the alternative pathway of activation by FH. Studies based on SPR [12], non-
reducing SDS-PAGE [51] and analytical ultracentrifugation have reported dimerization in FH. 
Furthermore, X-ray scattering studies have demonstrated two dimerization sites at SCR(6-8) and 
SCR(15-18) [47]. Our structural study of FH in solution using chemical cross-linking coupled with 
MS lens further support to the occurrence of dimerization in FH. We detected three interprotein cross-
links located in SCR20, confirming the presence of self-association sites within this module. 
Nevertheless, our study did not confirm the putative dimerization site in SCR(6-8) despite the 
presence of 14 well-exposed (SASA >30 Å2) lysine residues within this region of FH. 
Finally, our combined HRPF and MS study confirmed the flexibility of the full-size FH molecule in 
solution. Most importantly, our results demonstrate that several SCR modules may exhibit slightly 
different structural arrangements in the full-size FH molecule compared with previously described 
isolated modules (partial molecules). This finding will be useful, for example, for the design of anti-
FH antibodies, because antibodies produced from individual or concatenated modules antigens may 
exhibit differential binding activity on the full-size FH. The footprinting pattern is consistent with the 
known C3b binding sites such as the N-terminal SCR(1-4) modules that are protected by C3b from 
hydroxyl radical oxidation. Finally, our study provided new information on the central region of FH 
that may play a significant role in the folding of FH upon formation of the C3b-FH complex by 
bringing SCR(10-14) in the proximity to C3b and being involved in a conformational change upon 
formation of the C3b-FH complex. This study shows that HRPF combined MS has been valuably 
applied to the high molecular weight and flexible FH molecule. Its application to C3b and C3b in 
interaction with FH is under progress. 
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FIGURE LEGENDS 
 
Figure 1: Sequence coverage of irradiated Factor H. 
The Factor H sequence is shown in single-letter amino acid code. The individual short consensus 
repeats (SCRs) are indicated in brackets. The color of the amino-acid sequence indicates 
identification of the protein using tandem mass spectrometry (MS/MS): black, sequence not identified 
in MS/MS analysis; blue, sequence determined using MS (73%); red, oxidized amino acid: pink, 
glycosylation site; blue arrow: peptide identified as oxidized in unbound Factor H; green arrow, 
peptide identified as oxidized in the C3b-FH complex. 
 
Figure 2: Representative tandem mass spectra of peptides 92-109 (A) and 110-127 (B) obtained 
after 30 ms irradiation and trypsin digestion of Factor H. 
Mass shifts +16 Da (shown in green) indicate that oxidation occurred in positions Leu103 (A) and 
Ile120 (B). Peptide y-fragments are shown in red and b-fragments in blue.  
 
Figure 3: Comparison of oxidized sites in Factor H irradiated as an unbound protein and in a 
complex with C3b. 
A: Unbound Factor H (FH); B: FH irradiated in presence of C3b. FH is represented as a gray 
surface. The red spheres indicate oxidized residues. Orange circles highlight the FH regions showing 
differences in oxidative labeling between unbound FH and FH in complex with C3b. PDB ID: 3GAV-
1. 
 
Figure 4: Representation of oxidized residues H399, M414, Y449, and I474, located in short 
consensus repeat [7-8] of Factor H, on the crystallographic structure of C3b-FH[6-8] complexed 
with sucrose octasulfate [13]. 
Factor H is shown in blue, oxidized residues in yellow, and SNPs Y384H and Q382 in red. Sucrose 
octasulfate (SOS) is represented by black sticks.  
 
Figure 5: Representative dose-response plots showing the extent of unmodified FH peptides as a 
function of X-ray exposure time (ms). Dose-reponse plots were constructed for Factor H (FH) 
peptides identified in both unbound (black) and complexed (red) states of FH. 
 
Figure 6: Degree of protection of oxidized Factor H peptides defined as the ratio of oxidation of a 
given peptide in unbound FH to oxidation of the same peptide in the C3b-FH complex. 
Differences in oxidation rates less than 20% (corresponding to 0.8-1.2 fold change) are considered 
negligible. A decrease in the oxidation rate greater than 20% (≥1.2 fold) is considered as a 
significant decrease in solvent accessibility of the peptide, and thus its protection through the 
interaction between the protein of interest and its ligand. On the contrary, “the negative protection” 
degree (≤0.8 fold) indicates an increase in solvent accessibility of the investigated region. 
 
Figure 7: Surface representation of protected Factor H residues on the crystal structure of C3b-
FH[1-4] complex. 
The C3b surface is shown in gray, Factor H short consensus repeat modules [1-4] in blue, highly 
protected residues in red and moderately protected in orange. PDB ID: 2WII. 
 
Figure 8: Representative tandem mass spectra of BS3 cross-linked peptides 1165-1170/1165-1170 
(A) and 1169-1174/1165-1170 (B) derived from trypsin digestion of Factor H dimer. 
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Table 1: Oxidized residues identified by nano liquid chromatography-tandem mass spectrometry in 
unbound Factor H. 
Solvent-accessible surface area (SASA) values of residues belonging to short consensus repeats (SCR) 
[1-3] were calculated from the NMR solution structure (PDB ID: 2RLP for SCR[1-2] and 2RLQ for 
SCR[2-3]). SASA values of residues located in SCR[7-8] were calculated from the crystal structure of 
SCR[6-8] (His402 risk variant) in complex with sucrose octasulfate (SOS) (PDB ID: 2UWN) and 
SASA values of residues located in SCR9 were calculated from the crystal structure of SCR9 with 
choline binding protein (PDB ID: 4K12). SASA values of oxidized residues located in the central 
region of Factor H (FH) were calculated from the NMR solution structures of SCR[10-11] (PDB ID: 
4B2R), SCR[12-13] (PDB ID: 2KMS) and SCR[15-16] (PDB ID: 1HFH). The crystallographic 
structure of the C-terminus of FH (PDB ID: 3SW0) was used to determine SASA values for residues 
located in SCR18 and SCR20. 
The SAS values of residues Leu262, Leu826, Ile843 and Ile981 cannot be determined because there 
are no structural models for them. 
Please note that the residue numbering does not include the 18-residue long signal peptide. 
SCR 
Peptide 
range 
Sequence of oxidized peptide 
Oxidized 
amino 
acid 
SASA 
[Å2] 
PDB 
structure 
Structure type 
1 11-33 NTEILTGSWSDQTYPEGTQAIYK Tyr24 37.06 2RLP 
NMR  
Solution 
 
1 40-49 SLGNVIMVCR Met46 13.20 2RLP 
1 50-60 KGEWVALNPLR Val54 45.15 2RLP 
2 65-91 RPCGHPGDTPFGTFTLTGGNVFEYGVK Leu80 15.34 2RLP 
2 92-109 AVYTCNEGYQLLGEINYR Leu103 99.83 2RLP 
2 110-127 ECDTDGWTNDIPICEVVK Ile120 63.66 2RLP 
3 166-182 IEGDEEMHCSDDGFWSK His173 69.27 2RLQ 
5 248-259 SCDNPYIPNGDYSPLR Leu262 - - - 
7 393-406 SIDVACHPGYALPK His399 65.42 2UWN 
X-ray 
crystallography 
7 407-423 AQTTVTCMENGWSPTPR Met414 85.70 2UWN 
8 433-452 SSIDIENGFISESQYTYALK Tyr449 0.31 2UWN 
8 461-478 LGYVTADGETSGSITCGK Ile474 7.37 2UWN 
9 490-500 SCDIPVFMNAR Met497 59.53 4K12 
10 577-606 FSCKPGFTIVGPNSVQCYHFGLSPDLPICK Phe583 31.17 4B2R 
NMR  
Solution 
 
11 607-624 EQVQSCGPPPELLNGNVK Leu619 72.49 4B2R 
12 712-731 SITCIHGVWTQLPQCVAIDK His717 77.76 2KMS 
13 737-748 SSNLILEEHLK His746 120.95 2KMS 
14 817-836 VSVLCQENYLIQEGEEITCK Leu826 - - - 
14 840-849 WQSIPLCVEK Ile843 - - - 
16 941-954 CFEGFGIDGPAIAK Phe945 56.84 1HFH 
NMR  
Solution 
 
17 969-987 TDCLSLPSFENAIPMGEKK Ile981 - - - 
18 1027-1044 DTSCVNPPTVQNAYIVSR Ile1041 20.52 3SW0 X-ray 
crystallography 20 1154-1164 EIMENYNIALR Tyr1159 94.58 3SW0 
 
Table 2: Oxidized residues identified by nano liquid chromatography-tandem mass spectrometry of 
Factor H in the presence of C3b.  
Solvent-accessible surface area (SASA) values of residues belonging to short consensus repeat 
(SCR)1 were calculated from the NMR solution structure (PDB ID: 2RLP). SASA values of residues 
located in SCR[7-8] were calculated from the crystal structure of SCR[6-8] (His402 risk variant) in a 
complex with sucrose octasulfate (SOS) (PDB ID: 2UWN) and SASA values of residues located in 
SCR9 were calculated from the crystal structure of SCR9 complexed with choline binding protein 
(PDB ID: 4K12). SASA values of oxidized residues located in the central region of Factor H (FH) 
were calculated from the NMR solution structures of SCR[12-13] (PDB ID: 2KMS) and SCR[15-16] 
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(PDB ID: 1HFH). The crystallographic structure of the C-terminus of FH (PDB ID: 3SW0) was used 
to determine SASA values for residues located in SCR18 and SCR20. SASA values of FH residues in 
complex with C3b were calculated from the crystal structures of SCR[1-4] in complex with C3b (PDB 
ID: 2WII) and SCR[19-20] in complex with C3d (PDB ID: 3OXU). 
The SASA values of residues Met497 and Ile981 cannot be determined because there are no structural 
models for them. 
SCR 
Peptide 
range 
Sequence of oxidized peptides 
Oxidized 
residue 
SASA 
[Å2] 
unbound 
SASA 
[Å2] 
complex 
PDB 
structure 
1 50-60 KGEWVALNPLR Val54 45.15 28.28 2RLP/2WII 
7 407-423 AQTTVTCMENGWSPTPR Met414 85.70 - 2UWN 
9 490-500 SCDIPVFMNAR Met497 - -  
13 737-748 SSNLILEEHLK His746 120.95 - 2KMS 
16 915-940 SPPEISHGVVAHMSDSYQYGEEVTYK Met927 78.04 - 1HFH 
16 941-954 CFEGFGIDGPAIAK Phe945 56.84 - 1HFH 
17 969-987 TDCLSLPSFENAIPMGEKK Ile981 - -  
18 1027-1044 DTSCVNPPTVQNAYIVSR Ile1041 20.52 - 3SW0 
20 1154-1164 EIMENYNIALR Tyr1159 94.58 77.52 3SW0/3OXU 
 
Table 3: Cross-linked peptides of Factor H detected by nano liquid chromatography-tandem mass 
spectrometry. 
Factor H (FH) treated by the cross-linking reagent BS3 was separated by SDS-PAGE, and the 
monomer and dimer bands were in-gel digested. Resulting peptides were analyzed by nano liquid 
chromatography-tandem mass spectrometry. 
FH Modification Peptide sequence SCR Amino-acid sequence of peptides 
Dimer Interpeptide 187-193/ 240-247 3-4 CVEISCK-PLPSCEEK 
Dimer Interpeptide 229-239/ 1189-1192 4-20 GDAVCTESGWR-LSSR 
Dimer Interpeptide 453-456/ 61-64 8-1 EKAK-KCQK 
Dimer Interpeptide 625-628/ 868-678 11-15 EKTK-SSQESYAHGYK 
Dimer Interpeptide 732-736/ 737-748 13-13 LKKCK-SSNLIILEEHLK 
Dimer & monomer Interpeptide 868-878/ 1165-1168 15-20 SSQESYAHGYK-WTAK 
Dimer & monomer Intrapeptide 955-968 16 CLGEKWSHPPSCIK 
Dimer Interpeptide 1023-1026/ 1175-1184 18-20 PTCR-TGESVEFVCK 
Dimer Interpeptide 1165-1170/ 1165-1170 20-20 WTAKQK- WTAKQK 
Dimer Intrapeptide 1165-1174 20 WTAKQKLYSR 
Dimer Interpeptide 1169-1174/ 1165-1170 20-20 QKLYSR- WTAKQK 
Dimer Interpeptide 1169-1174/ 1169-1174 20-20 QKLYSR- QKLYSR 
Monomer Dead-end 737-751 13 SSNLIILEEHLKNKK 
SCR, short consensus repeat 
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Figure 1 
 
 
 
 
 
                              10         20         30         40         50         60         70          
            EDCNELPPRR NTEILTGSWS DQTYPEGTQA IYKCRPGYRS LGNVIMVCRK GEWVALNPLR KCQKRPCGHP 
 
 
 
        80         90        100        110        120        130        140        150        160 
GDTPFGTFTL TGGNVFEYGV KAVYTCNEGY QLLGEINYRE CDTDGWTNDI PICEVVKCLP VTAPENGKIV SSAMEPDREY HFGQAVRFVC  
 
 
 
       170        180        190        200        210        220        230        240        250 
NSGYKIEGDE EMHCSDDGFW SKEKPKCVEI SCKSPDVING SPISQKIIYK ENERFQYKCN MGYEYSERGD AVCTESGWRP LPSCEEKSCD 
 
 
 
       260        270        280        290        300        310        320        330        340 
NPYIPNGDYS PLRIKHRTGD EITYQCRNGF YPATRGNTAK CTSTGWIPAP RCTLKPCDYP DIKHGGLYHE NMRRPYFPVA VGKYYSYYCD  
 
 
 
       350        360        370        380        390        400        410        420        430 
EHFETPSGSY WDHIHCTQDG WSPAVPCLRK CYFPYLENGY NQNYGRKFVQ GKSIDVACHP GYALPKAQTT VTCMENGWSP TPRCIRVKTC  
 
 
 
       440        450        460        470        480        490        500        510        520 
SKSSIDIENG FISESQYTYA LKEKAKYQCK LGYVTADGET SGSITCGKDG WSAQPTCIKS CDIPVFMNAR TKNDFTWFKL NDTLDYECHD  
 
 
 
       530        540        550        560        570        580        590        600        612 
GYESNTGSTT GSIVCGYNGW SDLPICYERE CELPKIDVHL VPDRKKDQYK VGEVLKFSCK PGFTIVGPNS VQCYHFGLSP DLPICKEQVQ 
 
 
 
       620        630        640        650        660        670        680        690        700 
SCGPPPELLN GNVKEKTKEE YGHSEVVEYY CNPRFLMKGP NKIQCVDGEW TTLPVCIVEE STCGDIPELE HGWAQLSSPP YYYGDSVEFN 
 
 
 
       710        720        730        740        750        760        770        780        790 
CSESFTMIGH RSITCIHGVW TQLPQCVAID KLKKCKSSNL IILEEHLKNK KEFDHNSNIR YRCRGKEGWI HTVCINGRWD PEVNCSMAQI 
 
 
 
       800        810        820        830        840        850        860        870        880 
QLCPPPPQIP NSHNMTTTLN YRDGEKVSVL CQENYLIQEG EEITCKDGRW QSIPLCVEKI PCSQPPQIEH GTINSSRSSQ ESYAHGTKLS  
 
 
 
       890        900        910        920        930        940        950        960        970 
YTCEGGFRIS EENETTCYMG KWSSPPQCEG LPCKSPPEIS HGVVAHMSDS YQYGEEVTYK CFEGFGIDGP AIAKCLGEKW SHPPSCIKTD 
 
 
 
       980        990       1000       1010       1020       1030       1040       1050       1060 
CLSLPSFENA IPMGEKKDVY KAGEQVTYTC ATYYKMDGAS NVTCINSRWT GRPTCRDTSC VNPPTVQNAY IVSRQMSKYP SGERVRYQCR  
 
 
 
      1070       1080       1090       1100       1110       1120       1130       1140       1150 
SPYEMFGDEE VMCLNGNWTE PPQCKDSTGK CGPPPPIDNG DITSFPLSVY APASSVEYQC QNLYQLEGNK RITCRNGQWS EPPKCLHPCV 
 
 
 
      1160       1170       1180       1190       1200       1210  
ISREIMENYN IALRWTAKQK LYSRTGESVE FVCKRGYRLS SRSHTLRTTC WDGKLEYPTC AKR  
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Figure 8A 
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Figure 8B 
 
 
 
 
 
 
 
